NCT03605836View on ClinicalTrials.gov

A Trial to Evaluate the Efficacy, Safety, and Tolerability of Centanafadine Sustained-release Tablets in Adults With Attention-deficit/Hyperactivity Disorder

PHASE3CompletedINTERVENTIONAL

Enrollment

590

Participants

Timeline

Start Date

January 16, 2019

Primary Completion Date

May 14, 2020

Study Completion Date

May 14, 2020

Conditions

Attention Deficit DisorderAttention Deficit Hyperactivity Disorder

Interventions

DRUG

Centanafadine SR

100 mg, BID, oral tablets

OTHER

Placebo

BID, oral tablet

DRUG

Centanafadine SR

200 mg, BID, oral tablets

Trial Locations (1)

32806

For additional information regarding sites, contact 844-687-8522, Orlando

All Listed Sponsors

lead

Otsuka Pharmaceutical Development & Commercialization, Inc.

INDUSTRY

NCT03605836 - A Trial to Evaluate the Efficacy, Safety, and Tolerability of Centanafadine Sustained-release Tablets in Adults With Attention-deficit/Hyperactivity Disorder | Biotech Hunter | Biotech Hunter